New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors

PURPOSE OF REVIEW: Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have emerged as a promising drug class for the treatment of diabetic kidney disease. Developed originally as glucose-lowering drugs by enhancing urinary glucose excretion, these drugs also lower many other renal and cardiovascula...

Descripción completa

Detalles Bibliográficos
Autores principales: Dekkers, Claire C. J., Gansevoort, Ron T., Heerspink, Hiddo J. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Microvascular Complications—Nephropathy (M Afkarian and B Roshanravan, Section Editors)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871636/
https://www.ncbi.nlm.nih.gov/pubmed/29589183
http://dx.doi.org/10.1007/s11892-018-0992-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871636/
https://www.ncbi.nlm.nih.gov/pubmed/29589183
http://dx.doi.org/10.1007/s11892-018-0992-6

Ejemplares similares